Average cost of multi drug-resistant tuberculosis treatment in Congo, Democratic Republic of the
Congo, Democratic Republic of the: Average cost of multi drug-resistant tuberculosis treatment was 896 constant 2022 US$ in 2024. ▼ Falling
Average cost of multi drug-resistant tuberculosis treatment in Congo, Democratic Republic of the, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
In 2024, average cost of multi drug-resistant tuberculosis treatment in Congo, Democratic Republic of the stood at 896 constant 2022 US$.
The figure is up 1.7% on the previous year and down 61.5% over ten years.
That places Congo, Democratic Republic of the 54th out of 92 countries with data for 2024, putting it in the middle of the range.
Average cost of multi drug-resistant tuberculosis treatment in Congo, Democratic Republic of the, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 2,330 constant 2022 US$ | — |
| 2018 | 624 constant 2022 US$ | -73.2% |
| 2019 | 1,042 constant 2022 US$ | +67.0% |
| 2020 | 913 constant 2022 US$ | -12.4% |
| 2021 | 949 constant 2022 US$ | +3.9% |
| 2022 | 1,061 constant 2022 US$ | +11.8% |
| 2023 | 881 constant 2022 US$ | -17.0% |
| 2024 | 896 constant 2022 US$ | +1.7% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 1,332 constant 2022 US$ | 624 constant 2022 US$ | 2,330 constant 2022 US$ | 3 |
| 2020s | 940 constant 2022 US$ | 881 constant 2022 US$ | 1,061 constant 2022 US$ | 5 |
Countries ranked near Congo, Democratic Republic of the
More health data for Congo, Democratic Republic of the
- Un projection of annual infant deaths, annual growth rate -1.56 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.03 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 821.4 deaths per 1,000 people (2090)
- Number of infants who die before age 1 133,650 deaths (2100)
- Population ages 0-14, female, annual growth rate 3.04 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0.0003 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.2292 units per person (2025)
- Population ages 0-14, male, annual growth rate 3.09 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0.0003 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.2303 units per person (2025)
Frequently asked questions
- What is average cost of multi drug-resistant tuberculosis treatment in Congo, Democratic Republic of the?
- Average cost of multi drug-resistant tuberculosis treatment in Congo, Democratic Republic of the was 896 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of multi drug-resistant tuberculosis treatment recorded in Congo, Democratic Republic of the?
- The highest recorded value was 2,330 constant 2022 US$ in 2017.
- What is the lowest average cost of multi drug-resistant tuberculosis treatment recorded in Congo, Democratic Republic of the?
- The lowest recorded value was 624 constant 2022 US$ in 2018.
- How does Congo, Democratic Republic of the rank for average cost of multi drug-resistant tuberculosis treatment?
- Congo, Democratic Republic of the ranks 54th out of 92 countries with data for 2024.
- Is average cost of multi drug-resistant tuberculosis treatment rising or falling in Congo, Democratic Republic of the?
- Over the last ten years it is down 61.5%. The long-run trend across the full record is falling.
- Where does this Congo, Democratic Republic of the data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of multi drug-resistant tuberculosis treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.